ALLMedicine™ Myelodysplastic Syndrome Center
Research & Reviews 3,466 results
https://doi.org/10.1111/bjh.18330
British Journal of Haematology; Kotmayer L, Romero-Moya D et. al.
Jun 27th, 2022 - The importance of predisposition to leukaemia in clinical practice is being increasingly recognized. This is emphasized by the establishment of a novel WHO disease category in 2016 called "myeloid neoplasms with germline predisposition". A major s...
https://doi.org/10.1111/jth.15802
Journal of Thrombosis and Haemostasis : JTH; Taparia K, Wall E et. al.
Jun 26th, 2022 - The diagnosis of immune thrombocytopenia (ITP) is one of exclusion. While guidelines recommend against routine bone marrow examination (BME) at time of ITP diagnosis, the role of BME in relapsed/refractory ITP is unclear. To examine the frequency ...
https://doi.org/10.1007/s11899-022-00666-4 10.1016/j.ajhg.2010.12.006 10.1086/302637 10.1182/blood.V96.1.118 10.1159/000071812 10.1111/j.1538-7836.2010.03979.x 10.5482/ha12050001 10.1007/s00439-012-1215-x 10.1016/j.ejmg.2018.01.014 10.3109/09537104.2016.1171305 10.1038/ng.3253 10.1182/blood-2013-04-499319 10.1038/ejhg.2008.89 10.1038/leu.2015.236 10.1002/ajh.26321 10.1038/gim.2012.176 10.1038/bcj.2015.41 10.1038/gim.2015.30 10.1056/NEJMsr1406261 10.1007/s00431-015-2549-x 10.1038/s41586-020-2308-7 10.1182/blood-2013-03-489344 10.1186/s13045-016-0382-y 10.1038/ng.3469 10.1016/j.mayocp.2019.12.013 10.1007/s12185-013-1351-7 10.1053/j.seminhematol.2014.08.001 10.1182/blood-2013-06-506873 10.1111/j.1365-2141.1991.tb04529.x 10.1080/10428194.2016.1265118 10.1371/journal.pgen.1005262 10.1038/ng.3177
Current Hematologic Malignancy Reports; Sullivan MJ, Palmer EL et. al.
Jun 26th, 2022 - This review describes ANKRD26-related thrombocytopenia (RT) from a molecular, clinical, and laboratory perspective, with a focus on the clinical decision-making that takes place in the diagnosis and management of families with ANKRD26-RT. ANKRD26-...
https://doi.org/10.1111/jcpt.13712
Journal of Clinical Pharmacy and Therapeutics; Zhang R, Han B
Jun 25th, 2022 - Patients with low-risk myelodysplastic syndrome (MDS) and aplastic anaemia (AA) often need transfusions, which may accelerate iron overload. The aim of this study was to evaluate the efficacy, safety and dose-effect relationships of deferasirox (D...
https://clinicaltrials.gov/ct2/show/NCT01174108
Jun 24th, 2022 - Allogeneic hematopoietic stem cell transplantation (aHSCT) can cure patients with a variety of bone marrow failure syndromes (BMFS) including severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH) or myelodysplastic syndrome (MDS)...
Guidelines 2 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811170
Blood Malcovati L, Hellström-Lindberg E et. al.
Aug 28th, 2013 - Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the lit...
https://doi.org/10.3324/haematol.13755
Haematologica Bennett JM, Orazi A
Jan 16th, 2009 - Members of the French-American-British Cooperative Leukemia Working Group met to review cases of aplastic anemia, hypocellular myelodysplastic syndrome and hypocellular acute myeloid leukemia. Criteria were proposed and modified following three wo...
Drugs 33 results see all →
Clinicaltrials.gov 795 results
https://clinicaltrials.gov/ct2/show/NCT04401748
Jun 24th, 2022 - Myelodysplastic Syndrome (MDS) is a group of disorders that gradually affect the ability of a person's bone marrow (semi-liquid tissue present in many bones like backbones) to produce normal blood cells. Some people with MDS have a risk of the dis...
https://clinicaltrials.gov/ct2/show/NCT01174108
Jun 24th, 2022 - Allogeneic hematopoietic stem cell transplantation (aHSCT) can cure patients with a variety of bone marrow failure syndromes (BMFS) including severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH) or myelodysplastic syndrome (MDS)...
https://clinicaltrials.gov/ct2/show/NCT00923442
Jun 24th, 2022 - Background: Laboratory-based investigations have contributed to an improved understanding of pathophysiology and to the development of new therapies for hematologic malignancies. The aim of this protocol is to facilitate biologic study of leukemia...
https://clinicaltrials.gov/ct2/show/NCT01861106
Jun 24th, 2022 - Background: Genetic and sporadic mutations on one allele of the GATA2 gene lead to a syndrome termed MonoMAC. MonoMAC is characterized by: 1) infections with Mycobacterium avium complex (MAC) and other opportunistic infections, 2) deficiency of mo...
https://clinicaltrials.gov/ct2/show/NCT03520647
Jun 24th, 2022 - Severe aplastic anemia (SAA),myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH) are life-threatening bone marrow disorders. For SAA patients, long term survival can be achieved with immunosuppressive treatment. However, ...
News 436 results
https://www.mdedge.com/dermatology/article/255144/mixed-topics/sweet-syndrome-pulmonary-involvement-preceding-development
David Y. Chen, MD, PhD, Arthur Z. Eisen, MD
Jun 2nd, 2022 - To the Editor: A 59-year-old man was referred to our clinic for a rash, fever, and night sweats following treatment for metastatic seminoma with cisplatin and etoposide. Physical examination revealed indurated erythematous papules and plaques on t.
https://www.mdedge.com/familymedicine/article/254791/dermatology/ulcer-knuckle
MDedge Family Medicine;
May 26th, 2022 - Since the papules were worrisome for vasculitis, 2 punch biopsies were performed on smaller, younger lesions on the hand and 1 was submitted for direct immunofluorescence. Findings revealed a leukocytoclastic vasculitis (LCV) with prominent immuno.
https://www.onclive.com/view/fda-lifts-partial-clinical-hold-placed-on-studies-evaluating-magrolimab-in-mds-and-aml
May 7th, 2022 - The FDA has lifted a partial clinical hold that had been placed on studies examining magrolimab in combination with azacitidine following a review of comprehensive safety data collected from each trial, according to an announcement from Gilead Sci...
https://www.onclive.com/view/fda-grants-fast-track-status-to-prgn-3006-for-relapsed-refractory-aml
May 2nd, 2022 - The FDA has granted a fast track designation to the multigenic autologous CAR T-cell therapy PRGN-3006 for use as a potential therapeutic option in patients with relapsed or refractory acute myeloid leukemia (AML), according to an announcement fro...
https://www.onclive.com/view/liso-cel-continues-to-demonstrate-clinical-responses-in-relapsed-refractory-lbcl-at-2-year-follow-up
Apr 25th, 2022 - The utilization of lisocabtagene maraleucel (liso-cel; Breyanzi) in patients with relapsed/refractory large B-cell lymphomas (LBCL) produced durable outcomes at a 2 years follow-up, according to results from the phase 1 TRANSCEND NHL 001 trial (NC...
